GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction

Wei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin · 2026

Read GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction by Wei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13598195.txt.

Description

Wei Hu and ten colleagues published a pan-cancer study in two thousand twenty-six on a sugar-processing enzyme called GPI. The enzyme sits in a core energy pathway and shows up in tumour growth. Its value as a marker across cancers was not fully mapped.

Database analyses found the enzyme raised in twenty-nine cancers and lowered in three. High levels tracked with advanced stage, spread, and poor survival. Its level also tied to stem-like traits, immune cell mixes, and likely drug responses. In brain tumour cells, boosting the enzyme sped growth and invasion; silencing it slowed both. The authors call GPI a candidate marker for diagnosis, outlook, and treatment choice, with more mechanism work needed.

Catalog record

CREATORWei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE76 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13598195

Browse the full library · About the Tower of Babel